Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Cahn

Showing results (151-160 of 207) with videos related to

Pageof 21
Sort By:
BMC Public Health|May 27, 2011
Asking the right questions: developing evidence-based strategies for treating HIV in women and childrenQuarraisha Abdool Karim, Anchilla Banegura, Pedro Cahn, et al.
Research Square|March 31, 2025
Integrative Functional Genomics Analysis of Kaposi Sarcoma CohortsEzequiel Lacunza, Valeria Fink, Julian Naipauer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 18, 2011
Cancer in HIV-infected persons from the Caribbean, Central and South AmericaValeria I Fink, Bryan E Shepherd, Carina Cesar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 18, 2018
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority TrialPedro Cahn, Paul E Sax, Kathleen Squires, et al.
Scientific Reports|October 10, 2025
Integrative functional genomics analysis of Kaposi sarcoma cohortsEzequiel Lacunza, Valeria Fink, Julián Naipauer, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 29, 2022
Late-onset opportunistic infections while receiving anti-retroviral therapy in Latin America: burden and risk factorsIsaac Núñez, Brenda Crabtree-Ramirez, Bryan E Shepherd, et al.
Plos One|September 3, 2011
Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimenPedro Cahn, Julio Montaner, Patrice Junod, et al.
The Lancet. HIV|March 30, 2018
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean-Michel Molina, Kathleen Squires, Paul E Sax, et al.
Journal of Virology|April 26, 2013
Early Gag immunodominance of the HIV-specific T-cell response during acute/early infection is associated with higher CD8+ T-cell antiviral activity and correlates with preservation of the CD4+ T-cell compartmentGabriela Turk, Yanina Ghiglione, Juliana Falivene, et al.
International Journal of STD & AIDS|March 24, 2026
Penile human papilloma virus (HPV) in high risk populations with and without HIV: Epidemiological insights from ArgentinaDiego Daniel Salusso, Ana Gun, Agustin Nava, et al.
Pageof 21

Showing results (151-160 of 207) with videos related to

Sort By:
Pageof 21
BMC Public Health|May 27, 2011
Asking the right questions: developing evidence-based strategies for treating HIV in women and childrenQuarraisha Abdool Karim, Anchilla Banegura, Pedro Cahn, et al.
Research Square|March 31, 2025
Integrative Functional Genomics Analysis of Kaposi Sarcoma CohortsEzequiel Lacunza, Valeria Fink, Julian Naipauer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 18, 2011
Cancer in HIV-infected persons from the Caribbean, Central and South AmericaValeria I Fink, Bryan E Shepherd, Carina Cesar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 18, 2018
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority TrialPedro Cahn, Paul E Sax, Kathleen Squires, et al.
Scientific Reports|October 10, 2025
Integrative functional genomics analysis of Kaposi sarcoma cohortsEzequiel Lacunza, Valeria Fink, Julián Naipauer, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 29, 2022
Late-onset opportunistic infections while receiving anti-retroviral therapy in Latin America: burden and risk factorsIsaac Núñez, Brenda Crabtree-Ramirez, Bryan E Shepherd, et al.
Plos One|September 3, 2011
Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimenPedro Cahn, Julio Montaner, Patrice Junod, et al.
The Lancet. HIV|March 30, 2018
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean-Michel Molina, Kathleen Squires, Paul E Sax, et al.
Journal of Virology|April 26, 2013
Early Gag immunodominance of the HIV-specific T-cell response during acute/early infection is associated with higher CD8+ T-cell antiviral activity and correlates with preservation of the CD4+ T-cell compartmentGabriela Turk, Yanina Ghiglione, Juliana Falivene, et al.
International Journal of STD & AIDS|March 24, 2026
Penile human papilloma virus (HPV) in high risk populations with and without HIV: Epidemiological insights from ArgentinaDiego Daniel Salusso, Ana Gun, Agustin Nava, et al.
Pageof 21